Tumor response and TP53 alterations or expression
| Patient No | Cohort | Best response | PFS (days) | TP53 | IHC |
| R-003 | 1 | PD | 56 | N/A | Null |
| R-004 | 1 | PR | 365 | TP53 C125Y | N/A |
| R-005 | 1 | SD | 120 | N/A | Overexpression |
| R-006 | 2 | PR | 196 | TP53R342* | Overexpression |
| R-007 | 2 | PD | 52 | TP53 D259V | Overexpression |
| R-008 | 2 | SD | 170 | TP53 R175H | Overexpression |
| R-009 | 3 | PR | 313 | TP53 R273C | Overexpression |
| R-010 | 3 | PD | 30 | TP53 R213* | Null |
| R-011 | 3 | PD | 62 | TP53 G105fs*18 | Null |
| C001 | 3 | SD | 81 | TP53 E286Q | N/A |
| C002 | 3 | PR | 177 | TP53 R175H | N/A |
| C003 | 3 | SD | 94 | TP53 H179R | N/A |
| C004 | 3 | SD | 100 | No mutations reported | WT |
| C005 | 3 | PR | 279 | TP53 C238W | N/A |
IHC, immunohistochemistry; NA, not available; PD, progressive disease; PFS, progression free survival; PR, partial response; SD, stable disease; WT, wild type.